

Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering

Zofingen, 12 June 2024

**expect
more**



Safe harbor statement

This document is solely for use in connection with the presentation held by Siegfried Holding AG. It is furnished to you for your information and you may not reproduce it or redistribute to any other person. No representation or warranty, express or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Siegfried Holding AG shall not have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document may contain forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as "may", "plans", "expects", "believes" and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward looking statements.

This document does not constitute or form part of an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. In particular, this document does not constitute an offering prospectus under Swiss laws nor does it contain an offer of securities for sale in the United States; securities may not be offered or sold in the United States absent registration or exemption from registration.

The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

By participating in the presentation or by accepting any copy of this document, you agree to be bound by the foregoing.

Siegfried to acquire early-phase CDMO in Wisconsin (US) from Curia

Expanding customer offering in the US and strengthening service portfolio globally


- Siegfried to acquire a CDMO specialized in early-phase development and manufacturing services in Grafton, Wisconsin (US), from Curia
- The new site is set to strengthen Siegfried's customer offering for Drug Substances in terms of capabilities and geography
- Siegfried will further develop the site into its North American **Siegfried Acceleration Hub** for early-phase CDMO services to generate attractive growth opportunities
- The acquisition is financed from existing funds. The outlook for 2024 and the mid-term financial targets remain unchanged




Acquisition taps into the strong clinical pipeline of small molecules

Small & medium-sized companies drive majority (>80%) of pre-clinical and early-phase projects

New drug approvals by US FDA




Total # of small molecules projects and products



Capturing attractive opportunities already at early clinical stages

Customers will benefit from synergies across all development phases all the way to commercial production




Acquisition will be an additional feeder into our world-class network

Mutually leveraging complementary capacities

New business

Process research & dev. centers

Large-scale manufacturing network



Process R&D center
with pilot plant



Large-scale manufacturing with
process excellence group



We continue to deliver our strategy EVOLVE

Grafton will further accelerate our growth story

Grow existing core



- Small molecule DS and DP
- Complex chemistry
- Oral / inhalation solid dosage forms
- Aseptic liquid dosage forms
- Integrated offering of DS and DP services

Add adjacencies

- Formulation and aseptic fill & finish of large molecules
- Particle technologies
- DP delivery systems
- Antibody drug conjugates (ADC)

Enter and grow new areas

- DS Antibodies
- Cell & gene therapy (CGT)
- Viral vectors
- Synthetic biology
- Data analytics

Acquisition of Grafton

Acquisition of two DP sites from Novartis in Barcelona (ES)

New large-scale production plant for high-value DS in Minden (DE)

High-potency capacity for DS and DP

Expansion of pre-filled syringe capacity for biologics in Hameln (DE)

Expansion of high-potency micro-nization capacity in Evionnaz (CH)

Acquisition of DINAMIQS and build-out of commercial capacities in Zurich (CH)





Q&A



Thank you for
your attention



22 August 2024

H1 Results

24 October 2024

Capital Markets Day

Learn more about Siegfried

Download our Annual Reports

Read more



Visit our investors portal

Read more



Learn more about Siegfried's offering

Read more

